Literature DB >> 5639642

Detection of primary hyperparathyroidism, with special reference to its occurrence in hypercalciuric females with "normal" or borderline serum calcium.

E R Yendt, R J Gagne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 5639642      PMCID： PMC1923835     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN： 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  18 in total

1.  NEUROPSYCHIATRIC DISORDERS IN PRIMARY HYPERPARATHYROIDISM. CLINICAL ANALYSIS WITH REVIEW OF THE LITERATURE.

Authors:  G KARPATI; B FRAME
Journal:  Arch Neurol       Date:  1964-04

2.  CORK STOPPERS AND HYPERCALCEMIA.

Authors:  F E SMITH; H REINSTEIN; L E BRAVERMAN
Journal:  N Engl J Med       Date:  1965-04-15       Impact factor: 91.245

3.  MYOPATHY IN METABOLIC BONE DISEASE.

Authors:  J W PRINEAS; A S MASON; R A HENSON
Journal:  Br Med J       Date:  1965-04-17

4.  Some problems of hyperparathyroidism.

Authors:  C E DENT
Journal:  Br Med J       Date:  1962-12-01

5.  Diagnosis of occult hyperparathyroidism by a new rapid calcium infusion test.

Authors:  R S GOLDSMITH; F E CECCARELLI
Journal:  J Urol       Date:  1963-03       Impact factor: 7.450

6.  Ionised, protein-bound, and complexed calcium in the plasma in primary hyperparathyroidism.

Authors:  H M LLOYD; G A ROSE
Journal:  Lancet       Date:  1958-12-13       Impact factor: 79.321

7.  Diagnosis of primary hyperparathyroidism. Clinical and laboratory aspects.

Authors:  F R KEATING
Journal:  JAMA       Date:  1961-11-11       Impact factor: 56.272

8.  The ultrafiltrable calcium of human serum. I. Ultrafiltration methods and normal values.

Authors:  T Y TORIBARA; A R TEREPKA; P A DEWEY
Journal:  J Clin Invest       Date:  1957-05       Impact factor: 14.808

9.  On certain physiologic responses to intravenous injection of calcium salts into normal hyperparathyroid and hypoparathyroid persons.

Authors:  J E HOWARD; T R HOPKINS; T B CONNOR
Journal:  J Clin Endocrinol Metab       Date:  1953-01       Impact factor: 5.958

10.  Parathyroid hormone in plasma in adenomatous hyperparathyroidism, uremia, and bronchogenic carcinoma.

Authors:  S A Berson; R S Yalow
Journal:  Science       Date:  1966-11-18       Impact factor: 47.728
View more
  14 in total

1.  Postmenopausal osteoporosis: toward resolution of the dilemma.

Authors: 
Journal:  West J Med       Date:  1976-08

Review 2.  Recent progress in calcium metabolism: clinical application.

Authors:  G S Gordan
Journal:  Calif Med       Date:  1971-05

Review 3.  The clinical physiology of calcium homeostasis, parathyroid hormone, and calcitonin. II.

Authors:  C R Kleeman; S G Massry; J W Coburn
Journal:  Calif Med       Date:  1971-04

4.  The co-existence of primary hyperparathyroidism and osteogenesis imperfecta.

Authors:  I S Salti; V H Nassar; S Bulos
Journal:  Can Med Assoc J       Date:  1973-04-07       Impact factor: 8.262

5.  Temporary remission of hypercalcemia in hyperparathyroidism induced by corticosteroids.

Authors:  D A Garcia; E R Yendt
Journal:  Can Med Assoc J       Date:  1968-11-30       Impact factor: 8.262

6.  Unsuspected hypercalcemia among adults in hospital.

Authors:  W A Finnis; M Cohanim; E R Yendt
Journal:  Can Med Assoc J       Date:  1981-09-15       Impact factor: 8.262

7.  Paraplegia due to osteitis fibrosa secondary to primary hyperparathyroidism: report of a case.

Authors:  A K Sarda; M Vijayaraghavan; M Kapur
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

8.  Hyperparathyroidism in pregnancy: case report and review of the literature.

Authors:  R D Wilson; T Martin; R Christensen; A H Yee; C Reynolds
Journal:  Can Med Assoc J       Date:  1983-11-01       Impact factor: 8.262

9.  Primary hyperparathyroidism: epidemiology, diagnosis and clinical picture.

Authors:  S Ljunghall; P Hellman; J Rastad; G Akerström
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352

10.  Renal calculi.

Authors:  E R Yendt
Journal:  Can Med Assoc J       Date:  1970-03-14       Impact factor: 8.262
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.